Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Matti Annala · SciRah

Researcher profile · Semantic Scholar

Matti Annala

Share profile

Matti Annala — researcher profile on SciRah

h-index: 43
Works: 163
Citations: 16K

Most-cited papers

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Matti Annala, G. Vandekerkhove, D. Khalaf, S. Taavitsainen +14 more
2018Cancer Discovery454 citations Open access
Semantic Scholar
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
D. Khalaf, Matti Annala, S. Taavitsainen, D. Finch +16 more
2019The Lancet Oncology312 citations Open access
Semantic Scholar
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
G. Vandekerkhove, W. Struss, Matti Annala, H. Kallio +15 more
2019European Urology174 citations Open access
Semantic Scholar
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
C. Herberts, Matti Annala, J. Sipola, Sarah W. S. Ng +18 more
2022Nature158 citations
Semantic Scholar
Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression
L. Latonen, Ebrahim Afyounian, A. Jylhä, J. Nättinen +8 more
2018Nature Communications155 citations Open access
Semantic Scholar
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
G. Vandekerkhove, J. Lavoie, Matti Annala, A. Murtha +16 more
2021Nature Communications154 citations Open access
Semantic Scholar
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
N. Fonseca, C. Maurice-Dror, C. Herberts, W. Tu +35 more
2024Nature Communications133 citations Open access
Semantic Scholar
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
N. Sundahl, G. Vandekerkhove, K. Decaestecker, Annabel Meireson +13 more
2019European Urology113 citations
Semantic Scholar
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
H. Kallio, R. Hieta, L. Latonen, Anniina Brofeldt +8 more
2018British Journal of Cancer91 citations Open access
Semantic Scholar
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
C. Herberts, A. Murtha, S. Fu, Gang-ping Wang +22 more
2020European Urology78 citations
Semantic Scholar
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Matti Annala, S. Taavitsainen, D. Khalaf, G. Vandekerkhove +16 more
2021Clinical Cancer Research77 citations
Semantic Scholar
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
E. Warner, C. Herberts, S. Fu, S. Yip +14 more
2021Clinical Cancer Research72 citations
Semantic Scholar
Fragmentomic analysis of circulating tumor DNA targeted cancer panels
K. Helzer, M. Sharifi, J. Sperger, Y. Shi +30 more
2023Annals of Oncology65 citations Open access
Semantic Scholar
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.
Matti Annala, S. Fu, J. Bacon, J. Sipola +24 more
2021Annals of Oncology64 citations Open access
Semantic Scholar
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
E. Ritch, S. Fu, C. Herberts, Gang-ping Wang +15 more
2019Clinical Cancer Research64 citations Open access
Semantic Scholar
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Martin Sjöström, S. Zhao, S. Levy, Meng Zhang +60 more
2022Cancer Research55 citations Open access
Semantic Scholar
Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer.
S. Tolmeijer, E. Boerrigter, T. Sumiyoshi, E. Kwan +12 more
2023Clinical Cancer Research53 citations Open access
Semantic Scholar
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
J. Bacon, Matti Annala, M. Soleimani, J. Lavoie +8 more
2020Clinical Genitourinary Cancer52 citations
Semantic Scholar
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer
S. Taavitsainen, Matti Annala, E. Ledet, K. Beja +6 more
2019JCO Precision Oncology48 citations Open access
Semantic Scholar
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.
S. Hotte, K. Chi, A. Joshua, D. Tu +19 more
2019Clinical Genitourinary Cancer47 citations
Semantic Scholar
Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
E. Chedgy, G. Vandekerkhove, C. Herberts, Matti Annala +14 more
2018Journal of Pathology45 citations
Semantic Scholar
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M. Kwan, Sarah W. S. Ng, S. Tolmeijer, L. Emmett +72 more
2025Nature Medicine44 citations
Semantic Scholar
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
E. Warner, K. Van der Eecken, A. Murtha, E. Kwan +21 more
2024Nature Cancer40 citations
Semantic Scholar
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
D. Khalaf, I. Aragón, Matti Annala, R. Lozano +51 more
2020Annals of Oncology38 citations Open access
Semantic Scholar
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.
A. Jayaram, A. Wingate, D. Wetterskog, V. Conteduca +26 more
2019JCO Precision Oncology34 citations Open access
Semantic Scholar
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
V. Genitsch, A. Kollár, G. Vandekerkhove, Jennifer Blarer +12 more
2019Urologic oncology32 citations Open access
Semantic Scholar
Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer
H. Kallio, K. Savolainen, T. Virtanen, L. Ryyppö +10 more
2024Life Science Alliance22 citations Open access
Semantic Scholar
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
V. Genitsch, A. Kollár, G. Vandekerkhove, Jennifer Blarer +12 more
2019Urologic oncology22 citations Open access
Semantic Scholar
Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.
D. Khalaf, Matti Annala, D. Finch, C. Oja +8 more
201822 citations
Semantic Scholar
Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
J. Bacon, D. C. Müller, E. Ritch, Matti Annala +9 more
2021European Urology Oncology21 citations
Semantic Scholar
Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection.
Emily S. Park, Justin Yan, Richard Ang, J. H. Lee +8 more
2018Lab on a Chip19 citations
Semantic Scholar
PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas
K. Rautajoki, S. Jaatinen, A. Tiihonen, Matti Annala +11 more
2022Scientific Reports14 citations Open access
Semantic Scholar
Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma
K. Nordfors, J. Haapasalo, Ebrahim Afyounian, Joonas Tuominen +8 more
2018Cold Spring Harbor molecular case studies10 citations Open access
Semantic Scholar
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer
N. Fonseca, K. Van der Eecken, C. Herberts, S. Verbeke +11 more
2022JCO Precision Oncology9 citations Open access
Semantic Scholar
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).
K. Chi, S. Mukherjee, F. Saad, E. Winquist +15 more
20209 citations
Semantic Scholar
AR and ERG drive the expression of prostate cancer specific long noncoding RNAs
A. Kohvakka, M. Sattari, Anastasia Shcherban, Matti Annala +7 more
2020Oncogene9 citations Open access
Semantic Scholar
Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer
J. Sipola, Aslı D. Munzur, Edmond M. Kwan, Clara C Y Seo +17 more
2024Cancer Research8 citations
Semantic Scholar
Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.
T. Sumiyoshi, Xiaofei Wang, E. Warner, A. Sboner +14 more
2023Journal of the National Cancer Institute8 citations
Semantic Scholar
Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression
Joonas Uusi-Mäkelä, Ebrahim Afyounian, Francesco Tabaro, T. Häkkinen +12 more
2020bioRxiv8 citations Open access
Semantic Scholar
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.
T. Virtanen, E. Kwan, K. Parekh, J. Bacon +53 more
2025Annals of Oncology6 citations Open access
Semantic Scholar
Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.
E. Kwan, M. Rushton, W. Tu, S. Hotte +16 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
ERBB2/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer.
G. Vandekerkhove, A. Murtha, David C. Müller, Maria Stephenson +29 more
2025Clinical Cancer Research5 citations
Semantic Scholar
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).
Edmond M. Kwan, M. Hofman, Sarah W. S. Ng, L. Emmett +16 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC).
K. Chi, S. Taavitsainen, N. Iqbal, C. Ferrario +15 more
2018Annals of Oncology5 citations Open access
Semantic Scholar
Author Correction: The evolutionary history of lethal metastatic prostate cancer
G. Gundem, P. Van Loo, B. Kremeyer, L. Alexandrov +26 more
2020Nature4 citations Open access
Semantic Scholar
Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors.
Kirsi J. Granberg, Annina Raita, Birgitta Lehtinen, A. Tiihonen +8 more
2020Histology and Histopathology4 citations
Semantic Scholar
Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)–directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
A. A. Rose, S. Hotte, E. Winquist, R. Macfarlane +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.
J. Lavoie, G. Vandekerkhove, Matti Annala, N. Sundahl +8 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.
K. Chi, S. Taavitsainen, N. Iqbal, C. Ferrario +16 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.
G. Vandekerkhove, J. Lavoie, Matti Annala, N. Sundahl +8 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Wyatt×37
Invite
A. Wyatt — researcher profile on SciRah
K. Chi×23
Invite
K. Chi — researcher profile on SciRah
G. Vandekerkhove×21
Invite
G. Vandekerkhove — researcher profile on SciRah
C. Herberts×18
Invite
C. Herberts — researcher profile on SciRah

×16

Invite

M. Nykter — researcher profile on SciRah

Invite

K. Beja — researcher profile on SciRah

S. Taavitsainen×12

Invite

S. Taavitsainen — researcher profile on SciRah

Invite

D. Khalaf — researcher profile on SciRah

Invite

M. Gleave — researcher profile on SciRah

Invite

E. Ritch — researcher profile on SciRah

Invite

E. Warner — researcher profile on SciRah

Invite

B. Eigl — researcher profile on SciRah